Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sosei Group ( (JP:4565) ) has issued an update.
Nxera Pharma has reported its first quarter 2025 results, highlighting significant operational progress and financial improvements. The company has secured key development and commercialization agreements, including the assignment of rights for cenerimod and a partnership for daridorexant, while advancing its partnered programs with Neurocrine Biosciences and Tempero Bio. Financially, Nxera saw a notable increase in revenue and a reduction in net loss, attributed to increased sales and strategic cost management.
More about Sosei Group
Nxera Pharma, formerly known as Sosei Heptares, is a biopharmaceutical company focused on leading innovation in Japan and globally. The company leverages its NxWave™ platform to develop promising candidates for major disease areas with unmet needs, and it is actively involved in partnerships and commercialization agreements across various regions.
YTD Price Performance: -5.83%
Average Trading Volume: 400
Technical Sentiment Signal: Buy
Current Market Cap: $558.8M
See more data about 4565 stock on TipRanks’ Stock Analysis page.